Veloxis Pharmaceuticals A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Veloxis Pharmaceuticals A/S
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
APAC Podcast: Significant Approvals, Diabetes And NASH In India, Japan M&A
Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at some of the most significant regional pharma stories of the past few weeks.
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- H. Lundbeck A/S, LifeCycle Pharma A/S
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.